Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

911.00INR
5:11am EST
Change (% chg)

Rs31.80 (+3.62%)
Prev Close
Rs879.20
Open
Rs880.50
Day's High
Rs917.80
Day's Low
Rs874.25
Volume
151,473
Avg. Vol
172,820
52-wk High
Rs965.90
52-wk Low
Rs552.50

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Ltd. (Sun) is an international pharmaceutical company. The Company manufactures and markets a variety of pharmaceutical formulations as branded generics, as well as generics in the United States, India and several other global markets. It operates through four segments, including US Generics, Indian... (more)

Overall

Beta: 0.62
Market Cap(Mil.): Rs1,844,889.00
Shares Outstanding(Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.17

Financials

  SUN.BO Industry Sector
P/E (TTM): 31.11 38.99 40.21
EPS (TTM): 28.63 -- --
ROI: -- 17.01 16.34
ROE: -- 17.53 17.27
Search Stocks

Deals of the day- Mergers and acquisitions

Jan 30 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

30 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

UPDATE 1-Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sells its interest in a generic anti-bacterial medicine, the Federal Trade Commission said on Friday.

30 Jan 2015

Deals of the day- Mergers and acquisitions

(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)

08 Dec 2014

CORRECTED-Deals of the day- Mergers and acquisitions

(Removes erroneous reference to Canadian Solar in Sharp Corp item)

08 Dec 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Kisan Ratilal Choksey Shares and Securities Private Limited
$69.00
Provider: Motilal Oswal Securities Ltd.
$150.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks